Trial reportBMC anesthesiology2025
Comparative effects of remimazolam and propofol on hemodynamic stability during sedation for painless gastroscopy: a randomized clinical trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effect of Lidocaine Spray on the Sedative Dose of Remimazolam During Gastroscopy in Adults: A Prospective, Randomized Dose-Response Trial Using an Up-Down Sequential Allocation Method.Drug design, development and therapy · 2026Trial
- Remimazolam tosylate vs. propofol: effects on anesthetic efficacy and renal function in living donor kidney transplantation.BMC anesthesiology · 2025Trial
- Determination of the median effective dose (ED₅₀) of oliceridine combined with propofol for inhibiting gastroscope insertion responses in adult patients undergoing painless gastroscopy.Frontiers in medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRemimazolam, a novel ultra-short-acting benzodiazepine, shows promise for sedation in endoscopic procedures. However, its cardiovascular effects during painless gastroscopy remain unclear. This study compared the effects of remimazolam and propofol on hemodynamic stability in patients undergoing painless gastroscopy using continuous non-invasive arterial pressure (CNAP) monitoring.
methodsA total of 300 patients scheduled for sedation during upper gastrointestinal endoscopy were randomly assigned to either the remimazolam group (Group R, n = 150) or the propofol group (Group P, n = 150). Group R received remimazolam tosilate (0.2 mg/kg), while Group P received propofol (2 mg/kg). Primary outcomes were mean arterial pressure (MAP) and cardiac output (CO), recorded at two time points: the start (T1) and completion (T2) of the examination. Secondary outcomes included adverse events such as injection-related pain, hypotension, hypoxemia, respiratory depression, and bradycardia.
resultsAt both assessment points, MAP was significantly higher in Group R than in Group P (82.5 vs. 75.0 mmHg at T1, p < 0.001; 82.0 vs. 77.0 mmHg at T2, p = 0.002). Additionally, CO was significantly higher in Group R (5.7 vs. 5.4 L/min, p = 0.017). The incidence of adverse events was greater in Group P compared to Group R, including injection pain (25.3% vs. 6.7%), hypotension (24.7% vs. 5.3%), hypoxia (5.3% vs. 0%), and bradycardia (14.7% vs. 0%).
conclusionBoth remimazolam and propofol provide effective sedation for painless gastroscopy. However, remimazolam offers superior hemodynamic stability and significantly fewer adverse events.
trial registrationThe study was subsequently documented in the Chinese Clinical Trial Registry (identifier: ChiCTR2300068901; registration date: March 1, 2023).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.